NEW YORK (GenomeWeb News) – Vermillion reported after the close of the market on Wednesday that its fourth quarter revenues rose 123 percent, thanks largely to an increase in its average revenue per test, year over year.

The company reported Q4 revenues of $805,000, up from $361,000 in Q4 2015.

Vermillion posted $680,000 in product revenues from sales of its OVA1 ovarian cancer test, and $125,000 in service revenue from its Aspira IVD business. All of Vermillion's revenues in Q4 2015 came from OVA1 sales.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.